Abstract :

Severe acute respiratory syndrome – coronavirus 2   is known to cause coronavirus disease (COVID-19), an infectious diseaseThe majority of those exposed to the virus can have moderate respiratory issues and can recover without the need for specific treatment. Some, on the other side, can become gravely unwell and require medication. People over the age of 65, as well as those with existing medical disorders such as cardiovascular risk factors, diabetes, severe pulmonary disease, or cancer, are often more likely to form serious illnesses. COVID-19 can make anyone sick and cause serious illness or even death at any age. The Omicron variation in SARS-CoV-2(severe acute respiratory syndrome coronavirus 2) is the newer coronavirus strain to be identified as a “variant of concern” by the World Health Organization (WHO). Researchers from everywhere in the world, including South Africa, are looking into this variety in order to fully comprehend different aspects of Omicron, but it might take a long time to learn everything there is to know. Due to the scarcity of studies, misinformation about the Omicron variation is spreading around the world, posing a serious threat to healthcare systems and everyday life. Here, we reviewed the finding and characteristics of the Omicron variant, compared the transmission capacity of the Omicron variant with other variants, discussed on the influence of the Omicron variation on the severity of COVID-19 in cancer as well as diabetic patients, and discussed potential strategies and treatments options to avoid and overcome the Omicron variant’s prevalence.

---

Keywords :

Characteristics, Omicron, Prevention strategies, SARS-CoV-2, Transmission capacity, Vaccination.

---

References :

1. WHO, “Update on omicron”, https://www.who.int/news/item/28-11-2021-update-on-omicron Nov (accessed November 30, 2021)
2. Fontanet A, Autran B, Lina B, Kieny MP, Karim SS, Sridhar D. SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet,397(10278), 2021, pp.9524. DOI:10.1016/S0140-6736(21)00370-6
3. Luo CH, Morris CP, Sachithanandham J, Amadi A, Gaston D, Li M, Swanson NJ, Schwartz M, Klein EY, Pekosz A, Mostafa HH, “Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Infectious Virus Loads Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals”, medRxiv [Preprint], Aug20,2021 DOI:10.1101/2021.08.15.21262077

4. Wang, Yaping, Ruchong Chen, Fengyu Hu, Yun Lan, Zhaowei Yang, Chen Zhan, Jingrong Shi et al., “Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China”, EClinicalMedicine,40,2021, pp.101129. DOI: 10.1016/j.eclinm.2021.101129
5. Townsend, Jeffrey P., Hayley B. Hassler, Zheng Wang, Sayaka Miura, Jaiveer Singh, Sudhir Kumar, Nancy H. Ruddle, Alison P. Galvani, and Alex Dornburg, “The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study.” The Lancet Microbe, 2(12),2021,pp.e666-e675.
6. Sachs, Jeffrey D., Salim Abdool Karim, Lara Aknin, Joseph Allen, Kirsten Brosbøl, Gabriela Cuevas Barron, Peter Daszak et al., “Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly”, The Lancet, 396(10257), 2020, pp. 1102-1124. DOI:10.1016/S0140-6736(20)31927-9
7. GISAID, “Tracking of variants”, hCov19Variants,https://www.gisaid.org/hcov19-variants/ (accessed November 30, 2021).
8. Volz, Erik, Swapnil Mishra, Meera Chand, Jeffrey C. Barrett, Robert Johnson, Lily Geidelberg, Wes R. Hinsley et al, “Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England”, Nature, 593(7858),2020, pp. 266-269. DOI:10.1038/s41586-021-03470-x
9. COVID-19 South African Online Portal, “COVID-19 South African Coronavirus News And Information Portal”, SA Corona Virus OnlinePortal,https://sacoronavirus.co.za/ (accessed December 2, 2021)
10. Karim, Salim S. Abdool, and Quarraisha Abdool Karim, “Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic”,The Lancet, 398(10317),2021, pp. 2126-21. DOI:10.1016/S0140-6736(21)02758-6.
11. Greaney, Allison J., Tyler N. Starr, Pavlo Gilchuk, Seth J. Zost, Elad Binshtein, Andrea N. Loes, Sarah K. Hilton et al., “Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition”, Cell host & microbe,29(1), 2021, pp.44-57. DOI: 10.1016/j.chom.2020.11.007.
12. Harvey, William T., Alessandro M. Carabelli, Ben Jackson, Ravindra K. Gupta, Emma C. Thomson, Ewan M. Harrison, Catherine Ludden et al., “SARS-CoV-2 variants, spike mutations and immune escape”, Nature Reviews Microbiology,19(7),2021,pp.409-424. DOI: 10.1038/s41579-021-00573-0.
13. WHO,“Coronavirus”,Who.int, https://www.who.int/healthtopics/coronavirus#tab=tab_3 (accessed January 2, 2022).
14. Mohiuddin, Md, and Kazuo Kasahara, “Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options”, Respiratory medicine,191,2021,pp.106716. DOI: 10.1016/j.rmed.2021.106716.

15. Pulliam, Juliet RC, Cari van Schalkwyk, Nevashan Govender, Anne von Gottberg, Cheryl Cohen, Michelle J. Groome, Jonathan Dushoff, Koleka Mlisana, and Harry Moultrie, “Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa”, MedRxiv, (preprint), 2021. DOI: 10.1101/2021.11.11.21266068.
16. GISAID,“Covariants”,Covariants.org, https://covariants.org/variants/21K.Omicron (accessed cited, December 7, 2021).
17. Korber, Bette, Will M. Fischer, Sandrasegaram Gnanakaran, Hyejin Yoon, James Theiler, Werner Abfalterer, Nick Hengartner et al., “Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus”,Cell,182(4),2020,pp.812-827,  DOI: 10.1016/j.cell.2020.06.043.
18. Plante, Jessica A., Yang Liu, Jianying Liu, Hongjie Xia, Bryan A. Johnson, Kumari G. Lokugamage, Xianwen Zhang et al, “Spike mutation D614G alters SARS-CoV-2 fitness”, Nature,592(7852),2021,pp.116-121. DOI: 10.1038/s41586-020-2895-3.
19. Volz, Erik, Verity Hill, John T. McCrone, Anna Price, David Jorgensen, Áine O’Toole, Joel Southgate et al., “Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity”, Cell,184(1),2021, pp.64-75. DOI: 10.1016/j.cell.2020.11.020.

20. Rubino, Francesco, Stephanie A. Amiel, Paul Zimmet, George Alberti, Stefan Bornstein, Robert H. Eckel, Geltrude Mingrone et al.,”New-onset diabetes in Covid-19″, New England Journal of Medicine,383(8),2020, pp.789-790. DOI:10.1056/NEJMc1917344.
21. WHO, “WHO recommends two new drugs to treatCOVID-19”,Who.int., https://www.who.int/news/item/14-01-2022-who-recommends-two-new-drugs-to-treat-covid-19 (accessed January 16, 2022).
22. Burki T. “Omicron variant and booster COVID-19vaccines”, https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00559-2/fulltext (accessed January 17, 2022).
23. WHO, “Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)”, Who.int, https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition (accessed January 16, 2022).
24. He X, Hong W, Pan X,Lu G, Wei X., “Severe acute respiratory syndrome coronavirus 2 Omicron variant: Characteristics and prevention”, MedComm,2,2021, pp.838-845. DOI:10.1002/mco2.11